Advertisement

Topics

The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis

2016-08-31 15:23:22 | BioPortfolio

Summary

Number of Patients:

Study group - Bronchiectasis that is not attributable to Cystic fibrosis

- Group 1 - Pulmonary Rehabilitation

- Group 2 - Standard care

Sample size - 20 in each arm

Study Design:

- Randomised controlled trial (RCT)

All patients who qualify for the study will undergo a detailed evaluation. Baseline assessment will include the following parameters:

- Anthropometry

- Pulmonary Function Tests and Respiratory muscle strength

- Cardiopulmonary Exercise Testing (CPET)

- Six Minute Walk Test (6MWT)

- Severity of dyspnoea (Dyspnoea scale)

- Limb muscle strength

- Inflammatory markers in the serum - C-reactive protein

- Quality of Life

Patients will then be randomized (using table of random numbers) to either the pulmonary rehabilitation group or the standard arm group. After 8 weeks of pulmonary rehabilitation, patients will again be reassessed by the aforementioned tools.

Description

METHODOLOGY

Type of study - Randomised controlled trial (RCT)

Study period - March 2014 to July 2016

Place of study - Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi

Study group - Bronchiectasis that is not attributable to Cystic fibrosis

- Group 1 - Pulmonary Rehabilitation (PR)

- Group 2 - Standard care

Sample size - 20 in each arm

The study requires patients to attend the pulmonary rehabilitation program twice a week for 8 weeks.

Consent will be taken from all patients prior to enrollment.

Exacerbations of bronchiectasis will be defined by the following criteria:

At least four of the following clinical signs and symptoms suggestive of an acute exacerbation of bronchiectasis over two consecutive days:

- Increase in sputum quantity

- Change in sputum colour

- Change in sputum viscosity

- Increase in cough

- Increase in dyspnoea

- Increase in fatigue/lethargy

- Fever (self-reported)

- Episode of haemoptysis

The number of acute pulmonary exacerbations per year in the previous years will be recorded.

All patients attending the out patient department of pulmonary department of All India Institute of Medical Sciences will be screened for recruitment in the study.

Baseline evaluation

All patients who qualify for the study will undergo a detailed evaluation. This will include demographic data, complete medical history and clinical examination including anthropometry. Baseline assessment will include the following parameters:

i. Anthropometry

ii. Pulmonary Function Tests and Respiratory muscle strength

iii. Cardiopulmonary Exercise Testing (CPET)

iv. Six Minute Walk Test (6MWT)

v. Severity of dyspnoea (Dyspnoea scale)

vi. Limb muscle strength

vii. Inflammatory markers in the serum - C-reactive protein

viii. Quality of Life

The participants will then be randomly assigned to receive either standard care alone or pulmonary rehabilitation. The randomisation will be completed by the creation of a random numbers table.

Intervention

Standard care group

Candidates randomized to the "standard care group" will receive standard care for bronchiectasis according to current guidelines. These participants will receive instruction and review of airway clearance therapy (ACT). Each participant will be provided with written information about bronchiectasis and education regarding self-management of the condition. Participants who have not been previously instructed in any ACT will be taught the active cycle of breathing technique. These participants will not receive any supervised exercise training.

Pulmonary rehabilitation group

Participants randomised to the Pulmonary Rehabilitation group will receive exercise training and regular instruction in self-management of ACT along with standard care. Patients will be enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine and Sleep disorders, All India Institute of Medical Sciences.

The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one will be at home. The patient will be asked to maintain a personal log recording the date, time, duration and type of exercise performed to ensure compliance, and these will be regularly reviewed and monitored.

The Rehabilitation Programme will include the following:

i. Patient education

ii. Exercise training

iii. Ventilator and breathing exercises

Outcome Assessment

The patients will be reassessed at the end of the 8 week training programme.

Primary outcome measures:

- Maximum exercise capacity - measured with the 6MWT (the primary outcome is the greatest distance walked) and the CPET (VO2 max)

- HRQoL measured with the St. George Respiratory Questionnaire

Secondary outcome measures:

- Change in the Leicester Cough Questionnaire

- Change in the C- reactive protein

- Change in the lung Functions

- Change in the anxiety and depressions score

- Change in the hand grip dynamometry

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Conditions

Non-cystic Fibrosis Bronchiectasis

Intervention

Pulmonary Rehabilitation

Location

Dr. Rohit Kumar
New Delhi
Delhi
India
110016

Status

Recruiting

Source

All India Institute of Medical Sciences, New Delhi

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-08-31T15:23:22-0400

Clinical Trials [2842 Associated Clinical Trials listed on BioPortfolio]

Pulmonary Rehabilitation in Non-Cystic Fibrosis Bronchiectasis

The purpose of this study is to assess the effect of pulmonary rehabilitation on the transport of secretions, inflammation and respiratory resistance, and its repercussions on the quality ...

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium

The purpose of the trial is to investigate if the use of inhaled colistimethate sodium administered twice daily for 12 months delays the time to the first pulmonary exacerbation compared t...

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS-2)

The purpose of the trial is to investigate if the use of inhaled colistimethate sodium, administered twice daily for 12 months via the I-neb System, delays the time to the first pulmonary ...

The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis

The purpose of this study is to determine whether the daily inhalation of nebulised hypertonic saline (6%) will decrease the incidence of pulmonary exacerbations and increase the quality o...

Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis - The Willow Study

Phase 2, randomized, double-blind, placebo-controlled study of INS1007 administered once daily for 24 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFBE). Approximately 240 s...

PubMed Articles [5596 Associated PubMed Articles listed on BioPortfolio]

Distinct 'Immuno-Allertypes' of Disease and High Frequencies of Sensitisation in Non-Cystic-Fibrosis Bronchiectasis.

Allergic sensitization is associated with poor clinical outcomes in asthma, chronic obstructive pulmonary disease and cystic fibrosis however its presence, frequency and clinical significance in non-C...

The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis.

Non-cystic fibrosis bronchiectasis (NCFB) is considered a chronic heterogenic pulmonary disease, characterized by the permanent and abnormal enlargement and thickening of bronchial walls, impaired muc...

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Cystic fibrosis is an inherited recessive disorder of chloride transport that is characterised by recurrent and persistent pulmonary infections from resistant organisms that result in lung function de...

Radioaerosol Imaging Predicts the Utility of Aerosolized Antifungal Therapy in Allergic Bronchopulmonary Aspergillosis.

A 10-year-old girl with a history of complicated cystic fibrosis was hospitalized for pulmonary exacerbation with allergic bronchopulmonary aspergillosis and severe right upper lobe bronchiectasis dia...

Pathophysiology and Genetics of Bronchiectasis Unrelated to Cystic Fibrosis.

Bronchiectasis is characterized by deregulated inflammatory response and recurrent bacterial infection resulting in progressive lung damage and an irreversible dilatation of bronchi and bronchioles. G...

Medical and Biotech [MESH] Definitions

A rehabilitation therapy for removal of copious mucus secretion from the lung of patients with diseases such as CHRONIC BRONCHITIS; BRONCHIECTASIS; PULMONARY ABSCESS; or CYSTIC FIBROSIS. The patient's head is placed in a downward incline (so the TRACHEA is inferior to the affected area) for 15- to 20-minute sessions.

An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)

A strain of mice widely studied as a model for cystic fibrosis. These mice are generated from embryonic stem cells in which the CFTR (cystic fibrosis transmembrane conductance regulator) gene is inactivated by gene targeting. As a result, all mice have one copy of this altered gene in all their tissues. Mice homozygous for the disrupted gene exhibit many features common to young cystic fibrosis patients, including failure to thrive, meconium ileus, and alteration of mucous and serous glands.

A group of interstitial lung diseases with no known etiology. There are several entities with varying patterns of inflammation and fibrosis. They are classified by their distinct clinical-radiological-pathological features and prognosis. They include IDIOPATHIC PULMONARY FIBROSIS; CRYPTOGENIC ORGANIZING PNEUMONIA; and others.

More From BioPortfolio on "The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...


Searches Linking to this Trial